ArticleClinical and translational gastroenterology2016
Hepatitis C Treatment and Barriers to Eradication.
Article in Clinical and translational gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03791814 (A Prospective Cohort Study to Improve HCV Care Using Multidisciplinary Approach to the Treatment of Chronic Hepatitis C in Dialysis Patients), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Cohort Study to Improve HCV Care Using Multidisciplinary Approach to the Treatment of Chronic Hepatitis C in Dialysis Patients: The MATCH-D Study
Who cites it
27 citing papers in PubMed.
- Trial
- Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design.Nature communications · 2026Article
- Comparison of a dual antibody and antigen HCV immunoassay to standard of care algorithmic testing.Journal of clinical microbiology · 2024Article
- Point-of-Care Testing for Hepatitis Viruses: A Growing Need.Life (Basel, Switzerland) · 2023Review
- Development of simple, rapid, and sensitive methods for detection of hepatitis C virus RNA from whole blood using reverse transcription loop-mediated isothermal amplification.Journal of clinical microbiology · 2023Article
- Phenotype and fate of liver-resident CD8 T cells during acute and chronic hepacivirus infection.PLoS pathogens · 2023Article
- The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment.Gut and liver · 2022Article
- Article
- Resource Management through Artificial Intelligence in Screening Programs-Key for the Successful Elimination of Hepatitis C.Diagnostics (Basel, Switzerland) · 2022Article
- Review
- Adenovirus-vectored T cell vaccine for hepacivirus shows reduced effectiveness against a CD8 T cell escape variant in rats.PLoS pathogens · 2021Article
- Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.Journal of viral hepatitis · 2021Article
- Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain.Scientific reports · 2020Article
- Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines.Science advances · 2020Article
- Hepatitis C Core-Antigen Testing from Dried Blood Spots.Viruses · 2019Article
- Machine learning models to predict disease progression among veterans with hepatitis C virus.PloS one · 2019Article
- Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.PloS one · 2019Article
- Genetic and structural insights into broad neutralization of hepatitis C virus by human VScience advances · 2019Article
- The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C.Journal of virus eradication · 2018Article
- A Guide to the Economics of Hepatitis C Virus Cure in 2017.Infectious disease clinics of North America · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current treatment for chronic hepatitis C (CHC) is highly efficacious, well-tolerated, and of short duration for the majority of patients. Despite the dramatic advances in therapy, there remain several barriers to disease eradication. These include deficiencies in screening, diagnosis, and access to care, and high cost of the direct-acting antiviral medications. In addition, incident cases and reinfection associated with injection drug use contribute to the persistent worldwide disease burden. This article will review the current CHC treatments, and outline the remaining gaps in therapy and barriers to disease eradication.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.